The Zhitong Finance App learned that Cansino Biotech (06185) once rose nearly 6%. As of press release, it had risen 4.69% to HK$18.32, with a turnover of HK$8.3079 million.

According to the news, Cansino Biotech announced that the freeze-dried Haemophilus influenzae type b (Hib vaccine) conjugate vaccine (Hib vaccine) developed by the company has been approved by the State Drug Administration and can carry out related clinical trials. Furthermore, the company recently announced that the recombinant pneumococcal protein vaccine it developed obtained positive initial results in phase I (including phase Ia and phase Ib) clinical trials. The company will evaluate and plan the next stage of PBPV research and development based on the preliminary results obtained in the phase I clinical trial.